The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Commentary|Articles|August 26, 2025
4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation
Author(s)Ashley Chan
Fact checked by: Chris Ryan
Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.
Advertisement
Advertisement
In 2025, social media platforms have become an invaluable tool to learn something quickly, connect with colleagues, and stay abreast with the latest news and trends across specialties. However, using these tools remains a double-edged sword, especially with the spread of misinformation, which is why Eric K. Singhi, MD, and Shruti Patel, MD, have taken it upon themselves to challenge misinformation about cancer on social media.
Related to this article
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
Advertisement
Advertisement